Business Context and Reporting Period
This Form 8-K Current Report was filed by Skye Bioscience, Inc. on February 9, 2023, regarding the closing of a material asset disposition. The report details the sale of the Company's most significant real estate asset, held by its wholly owned subsidiary Emerald Health Therapeutics, Inc. (EHT), to C3 Souvenir Holding, Inc. and related parties.
Key Financial Metrics
The transaction involves an aggregate purchase price of approximately $9,478,000. Upon closing on February 9, 2023, the Company received immediate cash proceeds of approximately $5,602,000. The remaining balance is structured as deferred payments with interest:
- Short-term Installments: $373,000 payable in five equal monthly installments from December 31, 2023, to April 30, 2024.
- Long-term Installments: $2,797,000 payable in three equal installments on the 18-month, 30-month, and 42-month anniversaries of the closing date.
The filing does not provide specific data on overall revenue, profit, operating cash flow, margins, or total debt levels for the Company outside of this specific transaction.
Material Changes
The primary material change is the conversion of a significant real estate asset into cash and receivables. A Second Amendment to the Stock Purchase Agreement was executed on February 9, 2023, to facilitate the closing by allowing the first installment to be paid via a promissory note, which was subsequently paid in full on February 10, 2023.
Outlook, Risks, and Management Commentary
Management confirmed the closing of the transaction via a press release issued on February 15, 2023. The filing does not contain forward-looking guidance, specific risk factors, or management commentary regarding the Company's broader operational outlook beyond the completion of this asset sale.
Investor Verification Checklist
- Verify the receipt of the initial $5,602,000 cash proceeds in the Company's bank accounts.
- Confirm the terms and interest rates of the deferred payment installments totaling $3,170,000.
- Review the Second Amendment to the Verdé-lite SPA (Exhibit 10.1) for any covenants or conditions attached to the deferred payments.
- Assess the impact of this asset sale on the Company's remaining liquidity and operational runway.